Many governments and the World Health Organization have changed COVID-19 policies based on the suspect data provided by a small U.S. based company.

The WHO and the UN announced a temporary halt on the use of hydroxychloroquine, but there were no changes in their COVID-19 polices.

The WHO and the UN announced a temporary halt on the use of hydroxychloroquine, but there were no changes in their COVID-19 polices.The Lancet and the New England Journal of Medicine published studies based on the data collected by the U.S. company Surgisphere. The data was of nearly 96,000 patients with COVID-19, who were admitted to 671 hospitals, and it was co-authored by the firm’s chief executive Sapan Desai.

The research suggested that antimalarial drugs such as hydroxychloroquine and chloroquine increase the risk of death and heart problems among hospitalized patients, concerning to the study the WHO and UN had temporarily paused the hydroxychloroquine trials, but they did not make any changes on COVID-19 policy. Also, the study was withdrawn over concerns about the data.

Meanwhile, WHO's Director-General announced that based on the available mortality data, the members of the committee have recommended that there are no reasons to modify the trial protocol and also suggested to continue its trial of hydroxychloroquine.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.